Ironwood Pharma (IRWD) Misses Q2 EPS by $6.96; Offers FY23 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to Ironwood Pharma (IRWD) Misses Q2 EPS by $6.96; Offers FY23 Revenue Guidance

Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance

August 8, 2023 7:00 AM EDT

LINZESS (Iinaclotide) EUTRx prescription demand growth increased 9% year-over-year; LINZESS U.S. net sales of $270 million, an increase of 9% year-over-year

Expands clinical utility of LINZESS with FDA approval for pediatric patients ages 6-17 years-old suffering from functional constipation (FC)

Strengthens GI development portfolio with acquisition of VectivBio Holding AG and its lead investigational asset, apraglutide, for the potential treatment of short bowel syndrome with intestinal failure

Completes STARS Phase III clinical trial enrollment; now expects topline data in March of 2024

BOSTON--(BUSINESS... More